SFRS16 Inhibitors
SFRS16 inhibitors encompass a range of compounds that interfere with the splicing machinery, an essential cellular process in which SFRS16 is engaged. These inhibitors work by targeting various components of the spliceosome or by binding to RNA, affecting the interactions necessary for SFRS16 to function correctly. Pladienolide B, Sudemycin D6, Meayamycin, and E7107 are compounds that inhibit the spliceosome by binding to the SF3b complex or other core components. This action results in an indirect inhibition of SFRS16 by preventing the necessary assembly of the spliceosome, a complex that is critical for SFRS16 to perform its splicing regulatory role.
Other compounds, such as Isoginkgetin and Madrasin, hinder the progression or completion of the splicing process by targeting specific proteins within the spliceosome, thereby affecting SFRS16's ability to engage in the regulation of splicing. Chlorhexidine, while not a traditional splicing inhibitor, can intercalate into RNA structures and potentially disrupt the RNA-protein interactions that are vital for SFRS16's function in RNA binding and regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B is a spliceosome inhibitor that targets the SF3b complex, a key component of the spliceosome to which SFRS16 may bind. This compound can inhibit the splicing activity by preventing the proper assembly of the spliceosome, potentially altering the splicing pattern of pre-mRNAs that SFRS16 regulates. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
Sudemycin D6 is another inhibitor of the spliceosome with specificity for the SF3b complex. By disrupting the function of the spliceosome, Sudemycin D6 can indirectly inhibit SFRS16 by preventing it from participating in pre-mRNA splicing, a crucial step in gene expression. | ||||||
Isoginkgetin | 548-19-6 | sc-507430 | 5 mg | $225.00 | ||
Isoginkgetin is a biflavonoid that acts as a splicing inhibitor. It can impede the progression of spliceosome complex assembly, which includes complexes that SFRS16 may associate with, thus indirectly inhibiting SFRS16's splicing activity. | ||||||
Madrasin | 374913-63-0 | sc-507563 | 100 mg | $750.00 | ||
Madrasin is a small molecule that selectively inhibits the spliceosome's Prp8 protein, a component of the catalytic core. SFRS16's function can be indirectly inhibited by Madrasin through its disruption of spliceosome assembly and function. | ||||||
Chlorhexidine | 55-56-1 | sc-252568 | 5 g | $103.00 | 3 | |
Chlorhexidine has been reported to intercalate into RNA structures. Although it is primarily an antimicrobial agent, its intercalative properties can perturb RNA-protein interactions, potentially affecting SFRS16's RNA binding activity. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
E7107 is a derivative of pladienolide and acts as a spliceosome inhibitor. By targeting the spliceosome, it can indirectly inhibit SFRS16 by disrupting its involvement in pre-mRNA splicing. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Spliceostatin A is a natural product that inhibits the spliceosome by targeting the SF3b complex. This can indirectly inhibit SFRS16 by preventing its association with the spliceosome and subsequent splicing regulation. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tetrocarcin A is an antibiotic that has been shown to have splicing inhibitory activity. It may indirectly inhibit SFRS16 by affecting spliceosome function and thus its ability to regulate splicing. | ||||||
Herboxidiene | 142861-00-5 | sc-506378 | 1 mg | $1009.00 | ||
Herboxidiene, also known as GEX1A, is a compound that perturbs splicing by targeting the SF3b complex. This can lead to an inhibition of SFRS16's splicing regulatory functions. | ||||||